These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

271 related items for PubMed ID: 24777335

  • 1. Heterogeneity in the expression of receptors in the human breast cancer metastasized to the brain.
    Rao PS, Labhart M, Mayhew SL, Thirumala S, Rao US.
    Tumour Biol; 2014 Jul; 35(7):7267-73. PubMed ID: 24777335
    [Abstract] [Full Text] [Related]

  • 2. Breast cancer with brain metastases: clinicopathologic features, survival, and paired biomarker analysis.
    Shen Q, Sahin AA, Hess KR, Suki D, Aldape KD, Sawaya R, Ibrahim NK.
    Oncologist; 2015 May; 20(5):466-73. PubMed ID: 25802405
    [Abstract] [Full Text] [Related]

  • 3. Discrepancies between biomarkers of primary breast cancer and subsequent brain metastases: an international multicenter study.
    Kaidar-Person O, Meattini I, Jain P, Bult P, Simone N, Kindts I, Steffens R, Weltens C, Navarria P, Belkacemi Y, Lopez-Guerra J, Livi L, Baumert BG, Vieites B, Limon D, Kurman N, Ko K, Yu JB, Chiang V, Poortmans P, Zagar T.
    Breast Cancer Res Treat; 2018 Jan; 167(2):479-483. PubMed ID: 28975433
    [Abstract] [Full Text] [Related]

  • 4. Discordances in estrogen receptor status, progesterone receptor status, and HER2 status between primary breast cancer and metastasis.
    Curtit E, Nerich V, Mansi L, Chaigneau L, Cals L, Villanueva C, Bazan F, Montcuquet P, Meneveau N, Perrin S, Algros MP, Pivot X.
    Oncologist; 2013 Jun; 18(6):667-74. PubMed ID: 23723333
    [Abstract] [Full Text] [Related]

  • 5. Discordances in ER, PR, and HER2 between primary breast cancer and brain metastasis.
    Jung J, Lee SH, Park M, Youn JH, Shin SH, Gwak HS, Yoo H.
    J Neurooncol; 2018 Apr; 137(2):295-302. PubMed ID: 29260362
    [Abstract] [Full Text] [Related]

  • 6. HER2 expression is a strong independent predictor of nodal metastasis in breast cancer.
    Ahmed AR.
    J Egypt Natl Canc Inst; 2016 Dec; 28(4):219-227. PubMed ID: 27756653
    [Abstract] [Full Text] [Related]

  • 7. Estrogen receptor-beta expression in invasive breast cancer in relation to molecular phenotype: results from the Nurses' Health Study.
    Marotti JD, Collins LC, Hu R, Tamimi RM.
    Mod Pathol; 2010 Feb; 23(2):197-204. PubMed ID: 19898422
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. NRF1 motif sequence-enriched genes involved in ER/PR -ve HER2 +ve breast cancer signaling pathways.
    Ramos J, Das J, Felty Q, Yoo C, Poppiti R, Murrell D, Foster PJ, Roy D.
    Breast Cancer Res Treat; 2018 Nov; 172(2):469-485. PubMed ID: 30128822
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Real-world data on discordance between estrogen, progesterone, and HER2 receptor expression on diagnostic tumor biopsy versus tumor resection material.
    Berghuis AMS, van Deurzen CHM, Koffijberg H, Terstappen LWMM, Sleijfer S, IJzerman MJ.
    Breast Cancer Res Treat; 2019 Jun; 175(2):451-458. PubMed ID: 30756285
    [Abstract] [Full Text] [Related]

  • 12. Menopausal Hormone Therapy use and breast cancer risk by receptor subtypes: Results from the New South Wales Cancer Lifestyle and EvaluAtion of Risk (CLEAR) study.
    Salagame U, Banks E, O'Connell DL, Egger S, Canfell K.
    PLoS One; 2018 Jun; 13(11):e0205034. PubMed ID: 30403669
    [Abstract] [Full Text] [Related]

  • 13. Estrogen/progesterone receptor and HER2 discordance between primary tumor and brain metastases in breast cancer and its effect on treatment and survival.
    Sperduto PW, Mesko S, Li J, Cagney D, Aizer A, Lin NU, Nesbit E, Kruser TJ, Chan J, Braunstein S, Lee J, Kirkpatrick JP, Breen W, Brown PD, Shi D, Shih HA, Soliman H, Sahgal A, Shanley R, Sperduto W, Lou E, Everett A, Boggs DH, Masucci L, Roberge D, Remick J, Plichta K, Buatti JM, Jain S, Gaspar LE, Wu CC, Wang TJC, Bryant J, Chuong M, Yu J, Chiang V, Nakano T, Aoyama H, Mehta MP.
    Neuro Oncol; 2020 Sep 29; 22(9):1359-1367. PubMed ID: 32034917
    [Abstract] [Full Text] [Related]

  • 14. Breast cancer biomarkers in clinical testing: analysis of a UK national external quality assessment scheme for immunocytochemistry and in situ hybridisation database containing results from 199 300 patients.
    Dodson A, Parry S, Ibrahim M, Bartlett JM, Pinder S, Dowsett M, Miller K.
    J Pathol Clin Res; 2018 Oct 29; 4(4):262-273. PubMed ID: 30066480
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Integrative investigation on breast cancer in ER, PR and HER2-defined subgroups using mRNA and miRNA expression profiling.
    Dai X, Chen A, Bai Z.
    Sci Rep; 2014 Oct 23; 4():6566. PubMed ID: 25338681
    [Abstract] [Full Text] [Related]

  • 17. The Role of Previous Therapies and Sites of Metastasis as Influencing Factors on Discordance of ER, PR and HER2 Status Between Primary and Metastasized Breast Cancer.
    Vogel C, Malter W, Morgenstern B, Ludwig S, Vehreschild JJ, Hamacher S, Mallmann P, Kirn V, Thangarajah F.
    Anticancer Res; 2019 May 23; 39(5):2647-2659. PubMed ID: 31092464
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.